Literature DB >> 12477299

Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.

N L Rasgon1, M S Carter, S Elman, M Bauer, M Love, S G Korenman.   

Abstract

We present the case of a young woman with treatment-resistant major depression, who presented to the Mood Disorders Clinic with a Hamilton Psychiatric Rating Scale for Depression (HAM-D-21) score of 28, after a year-long treatment with Effexor-XR. The patient also had untreated Polycystic Ovarian Syndrome (PCOS). The resolution of her depressive symptoms resulted from the treatment for PCOS with metformin and spironolactone. The patient remained euthymic 5 months after discontinuation of the antidepressant while continuing therapy for PCOS. We briefly overview of the pertinent literature of the pathophysiology of PCOS and affective disorders, highlighting an overlap in phenotypical presentations between these two disorders. Dysregulation of the hypothalamo-pituitary axis and various end organ systems are implicated in both PCOS and affective disorders. As such, several clinical and biochemical markers are common to both disorders, namely insulin resistance, obesity, and hyperandrogenism. In addition, these metabolic abnormalities are interrelated, causing women with PCOS or affective disorders to get caught in a "vicious cycle" of hormonal dysregulation. The case report presented here illustrates how treatment of symptoms such as insulin resistance and hyperandrogenism can lead to remission of major depressive disorder and PCOS. We suggest that through treatment of underlying metabolic defects, both the mood of the patient and the metabolic condition of PCOS can be assisted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477299

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  8 in total

1.  A case of major depressive disorder and symptoms of polycystic ovary syndrome responding to escitalopram.

Authors:  Sergio L Blay
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Associations between psychiatric disorders and menstrual cycle characteristics.

Authors:  Mary Lee Barron; Louise H Flick; Cynthia A Cook; Sharon M Homan; Claudia Campbell
Journal:  Arch Psychiatr Nurs       Date:  2008-10       Impact factor: 2.218

3.  Influence of sex steroid hormones on the adolescent brain and behavior: An update.

Authors:  Pilar Vigil; Juan Pablo Del Río; BÁrbara Carrera; Florencia C ArÁnguiz; Hernán Rioseco; Manuel E Cortés
Journal:  Linacre Q       Date:  2016-08

4.  Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice.

Authors:  Yeshwant Kurhe; R Mahesh; Thangaraj Devadoss
Journal:  Psychopharmacology (Berl)       Date:  2017-02-25       Impact factor: 4.530

Review 5.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

6.  Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests.

Authors:  Yeshwant Kurhe; Mahesh Radhakrishnan; Deepali Gupta
Journal:  Metab Brain Dis       Date:  2014-06-27       Impact factor: 3.584

7.  Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice.

Authors:  Yeshwant Kurhe; Radhakrishnan Mahesh
Journal:  Neurobiol Stress       Date:  2016-05-18

8.  Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study.

Authors:  N Rasgon; K W Lin; J Lin; E Epel; E Blackburn
Journal:  Transl Psychiatry       Date:  2016-01-05       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.